300M women world-wide suffer from Bacterial Vaginosis. Recurrence rates post treatment are typically 30-50% and antibiotics is the only recommended curative treatment. BV is also viewed as a gateway for STIs.
Each year more than 450M people are infected by the most common Sexually Transmitted Indications (Gonorrhea, Chlamydia, Trichomonas). In Gonorrhea alone the number is 100M per year and is growing by 10% annually. Several strains of Gonorrhea bacteria are resistant and there is no effective treatment available.
Combining product safety, efficacy and exclusion of AMR, the technology opens the opportunity for preventive treatment of both BV and STIs. We believe that safe, prophylactic treatment of these indications will provide significant health benefits to millions of men and women world-wide.
Clinical expert BV, Principal Investigator
Ex CMO J&J
Director WHO, STI Expert
MA TFS, Ex Clinical Dev Astra Zeneca
Founder and Executive Chairman Zephyr Health
Patent Attorney MDS Law
Patent Attorney Dehns
Ex CEO Hemocue